Clinical Trial Search Results
'Inventiva S.A. / “A randomised, double-blind, placebo- controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis”
'
'
This study is currently enrolling.
Inventiva S.A. (the Sponsor) is running a research study to see if an investigational drug named lanifibranor, not yet approved for marketing, will help in the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH) and ...
20190184: EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction
This study is currently enrolling.
This study is being done to learn whether regular healthcare, combined with early treatment with a cholesterol lowering drug called evolocumab (Repatha) reduces heart attack, stroke, procedures to improve blood flow and death, ...
5-Hydroxymethylation Patterns in cDNA from Patients Presenting with Suspicion of Ovarian Carcinoma
This study is currently enrolling.
The purpose of this research is to see if we can identify any markers in the blood which might be able to be used in a screening test for cancer. We are also interested in studying the changes in the blood over time of patients ...
: D926XC00001: Phase 3, Open-Label, Randomized Study of Datopotamab Deruxtecan with or without Durvalumab Versus Investigator’s Choice of Therapy in Patients with Stage I-III Triple Negative Breast Cancer who have Residual Invasive Disease in Breast and/or Axillary Lymph Nodes Following Neoadjuvant Systemic Therapy and Surgical Resection (TROPION-Breast03)
This study is currently enrolling.
We are doing this study to learn more about whether an investigational drug called datopotamab deruxtecan (also called Dato-DXd), either alone or in combination with another investigational drug called durvalumab, will work and ...
: PRT3789-01: A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 in Participants with Select Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
This study is currently enrolling.
The purpose of this research study is to test the safety of PRT3789 at different dose levels to find out what effects, good and/or bad, PRT3789 has on you and your type of cancer. The information collected from you and from oth ...
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (STELLAR-002)
This study is currently enrolling.
You are being asked to take part in a clinical research study called STELLAR-002 because you have been diagnosed with cancer or your cancer has worsened since your last treatment. If you join this study, you will receive an inv ...
A Double-blind, Randomized, Placebo-controlled, Multicenter Study
Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with
Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)
Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with
Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)
This study is currently enrolling.
Study 20180244 is a double-blind, randomized, placebo-controlled, multicenter outcomes study to assess the impact of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD) and e ...
A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic Syndrome (MDS)
This study is currently enrolling.
You are being asked to take part in this research study because you have been diagnosed with acute leukemia or myelodysplastic syndrome (MDS).
A Multi-center, Randomized, Double-blind, Placebo controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A
This study is currently enrolling.
The main purpose of this study is to investigate how effective PXT3003 is when compared to a placebo, on the disease progression and symptoms of CMT1A. The study also aims to assess the safety and tolerability (whether side ef ...